Sumitomo Pharma Co., Ltd.
DNPUFOTCHealthcare● Active
$10.50
+$1.13(+12.06%)
Market Cap$4.7B
P/E Ratio—
52W High$19.2
52W Low$6.34
Sumitomo Pharma Co., Ltd. (DNPUF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
DNPUF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$0.01
Est. -$0.10 · +86.6%
Revenue
$0.66B
Est. $0.63B · +6.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 5-Quarter EPS Beat Streak
DNPUF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | — | — | — | — | $0.73B | — |
| ▲ Q2 FY2026 | May 13, 2026 | -$0.10 | -$0.01 | +86.6% | $0.66B | $0.63B | +6.0% |
| ▲ Q1 FY2026 | Jan 30, 2026 | -$0.01 | $0.14 | +2651.3% | $0.77B | $0.66B | +17.4% |
| ▲ Q2 FY2025 | Jun 30, 2025 | $0.14 | $0.19 | +42.4% | $0.75B | $0.63B | +18.0% |
| ▲ Q2 FY2025 | May 13, 2025 | -$0.08 | $0.04 | +149.3% | $0.70B | $0.59B | +20.1% |
| ▲ Q1 FY2025 | Jan 31, 2025 | $0.26 | $0.86 | +225.5% | $0.72B | $0.59B | +21.4% |
| ▼ Q3 FY2024 | Sep 30, 2024 | $0.12 | -$0.82 | -753.3% | $0.61B | $0.61B | -0.8% |
| ▲ Q2 FY2024 | Jun 29, 2024 | -$0.07 | $0.25 | +480.7% | $0.56B | $0.51B | +10.8% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Beat
EPS Actual
-$0.01
EPS Est.
-$0.10
EPS Surpr.
+86.6%
Revenue
$0.66B
Q1 FY2026
Jan 30, 2026Beat
EPS Actual
$0.14
EPS Est.
-$0.01
EPS Surpr.
+2651.3%
Revenue
$0.77B
Q2 FY2025
Jun 30, 2025Beat
EPS Actual
$0.19
EPS Est.
$0.14
EPS Surpr.
+42.4%
Revenue
$0.75B
Q2 FY2025
May 13, 2025Beat
EPS Actual
$0.04
EPS Est.
-$0.08
EPS Surpr.
+149.3%
Revenue
$0.70B
Q1 FY2025
Jan 31, 2025Beat
EPS Actual
$0.86
EPS Est.
$0.26
EPS Surpr.
+225.5%
Revenue
$0.72B
Q3 FY2024
Sep 30, 2024Miss
EPS Actual
-$0.82
EPS Est.
$0.12
EPS Surpr.
-753.3%
Revenue
$0.61B
Q2 FY2024
Jun 29, 2024Beat
EPS Actual
$0.25
EPS Est.
-$0.07
EPS Surpr.
+480.7%
Revenue
$0.56B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $-15.34 | $-15.34 | $-15.34 | 1 |
| Q4 FY2025 | $-0.87 | $-0.87 | $-0.87 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $133B | $133B | $133B | 1 |
| Q4 FY2026 | $163B | $163B | $163B | 1 |
| Q3 FY2026 | $126B | $126B | $126B | 1 |
| Q2 FY2026 | $117B | $117B | $117B | 1 |
| Q1 FY2026 | $87.8B | $100B | $113B | 2 |
| Q4 FY2025 | $102B | $103B | $104B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 13, 2026 | +86.6% | $10.50 | $10.50 | +0.00% |
| ▲ Q1 FY2026 | Jan 30, 2026 | +2651.3% | $14.36 | $14.36 | +0.00% |
| ▲ Q2 FY2025 | Jun 30, 2025 | +42.4% | $6.55 | $6.55 | +0.00% |
| ▲ Q2 FY2025 | May 13, 2025 | +149.3% | $6.53 | $6.53 | +0.00% |
| ▲ Q1 FY2025 | Jan 31, 2025 | +225.5% | $4.00 | $4.00 | +0.00% |
| ▼ Q3 FY2024 | Sep 30, 2024 | -753.3% | $4.05 | $4.05 | +0.00% |
| ▲ Q2 FY2024 | Jun 29, 2024 | +480.7% | $2.26 | $2.42 | +7.08% |
| ▼ Q1 FY2024 | Mar 30, 2024 | -52.9% | No price data | $2.60 | — |
Q2 FY2026+0.00%
Report Date
May 13, 2026
EPS Beat/Miss
+86.6%
Price Before
$10.50
Price After
$10.50
Q1 FY2026+0.00%
Report Date
Jan 30, 2026
EPS Beat/Miss
+2651.3%
Price Before
$14.36
Price After
$14.36
Q2 FY2025+0.00%
Report Date
Jun 30, 2025
EPS Beat/Miss
+42.4%
Price Before
$6.55
Price After
$6.55
Q2 FY2025+0.00%
Report Date
May 13, 2025
EPS Beat/Miss
+149.3%
Price Before
$6.53
Price After
$6.53
Q1 FY2025+0.00%
Report Date
Jan 31, 2025
EPS Beat/Miss
+225.5%
Price Before
$4.00
Price After
$4.00
Q3 FY2024+0.00%
Report Date
Sep 30, 2024
EPS Beat/Miss
-753.3%
Price Before
$4.05
Price After
$4.05
Q2 FY2024+7.08%
Report Date
Jun 29, 2024
EPS Beat/Miss
+480.7%
Price Before
$2.26
Price After
$2.42
Q1 FY2024—
Report Date
Mar 30, 2024
EPS Beat/Miss
-52.9%
Price Before
—
Price After
$2.60
Avg Beat Reaction+1.18%
Avg Miss Reaction+0.00%
Beat Rate6 / 8 quarters
Largest Move+7.08% (Q2 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: DNPUF ends December
Sumitomo Pharma Co., Ltd. (DNPUF) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-0.01 — beating the analyst consensus of $-0.10 by +86.6%. DNPUF has beaten EPS estimates for 5 consecutive quarters. The next DNPUF earnings date is expected around September 1, 2026.
Each quarter, investors track DNPUF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. DNPUF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
DNPUF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
DNPUF earnings · 5 questionsSumitomo Pharma Co., Ltd.'s next earnings report is expected around September 1, 2026. DNPUF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; DNPUF historically reports after market close (AMC).
DNPUF earnings datewhen is DNPUF earningsDNPUF next earnings datewhen does DNPUF report earningsDNPUF earnings calendar
▸ Source: FMP · Sumitomo Pharma Co., Ltd. SEC filings · US GAAP · Sumitomo Pharma Co., Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026